Sarah Blagden
Professor of Experimental Oncology
- Lead for Oxford Cancer Trials Office (OCTO)
Recent publications
-
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Plummer R. et al, (2025), Cell Rep Med
-
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
-
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
Liu J. et al, (2025), J Clin Oncol
-
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.
Chettle J. et al, (2024), HGG Adv, 5
-
Access divergence to new cancer medicines in the United Kingdom.
Lythgoe MP. et al, (2024), Eur J Cancer, 207